IL162274A0 - A nucleic acid and protein designated 193p1e1b andcompositions containing the same - Google Patents

A nucleic acid and protein designated 193p1e1b andcompositions containing the same

Info

Publication number
IL162274A0
IL162274A0 IL16227402A IL16227402A IL162274A0 IL 162274 A0 IL162274 A0 IL 162274A0 IL 16227402 A IL16227402 A IL 16227402A IL 16227402 A IL16227402 A IL 16227402A IL 162274 A0 IL162274 A0 IL 162274A0
Authority
IL
Israel
Prior art keywords
andcompositions
nucleic acid
same
protein designated
193p1e1b
Prior art date
Application number
IL16227402A
Other languages
English (en)
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of IL162274A0 publication Critical patent/IL162274A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL16227402A 2001-12-07 2002-12-06 A nucleic acid and protein designated 193p1e1b andcompositions containing the same IL162274A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/013,312 US7449548B2 (en) 2001-12-07 2001-12-07 Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
PCT/US2002/039274 WO2003050255A2 (fr) 2001-12-07 2002-12-06 Acide nucleique et proteine correspondante appelee 193p1e1b utile dans le traitement et la detection du cancer

Publications (1)

Publication Number Publication Date
IL162274A0 true IL162274A0 (en) 2005-11-20

Family

ID=21759312

Family Applications (4)

Application Number Title Priority Date Filing Date
IL16227402A IL162274A0 (en) 2001-12-07 2002-12-06 A nucleic acid and protein designated 193p1e1b andcompositions containing the same
IL162274A IL162274A (en) 2001-12-07 2004-06-01 Nucleic acid and protein designated 193p1e1b and compositions containing the same
IL200608A IL200608A (en) 2001-12-07 2009-08-27 Methods for the detection of 193p1e1b protein and use of compositions containing a 193p1e1b protein or an antibody binding thereto
IL206243A IL206243A (en) 2001-12-07 2010-06-08 Antibody specifically binding a 193p1e1b protein

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL162274A IL162274A (en) 2001-12-07 2004-06-01 Nucleic acid and protein designated 193p1e1b and compositions containing the same
IL200608A IL200608A (en) 2001-12-07 2009-08-27 Methods for the detection of 193p1e1b protein and use of compositions containing a 193p1e1b protein or an antibody binding thereto
IL206243A IL206243A (en) 2001-12-07 2010-06-08 Antibody specifically binding a 193p1e1b protein

Country Status (7)

Country Link
US (7) US7449548B2 (fr)
EP (1) EP1517606A4 (fr)
JP (2) JP2005516593A (fr)
AU (1) AU2002362105B2 (fr)
CA (1) CA2469161A1 (fr)
IL (4) IL162274A0 (fr)
WO (1) WO2003050255A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449548B2 (en) * 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
US20080058272A1 (en) * 2006-08-29 2008-03-06 Juergen Becker Nonamer Peptides for Cancer Treatment
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
US10682399B2 (en) * 2012-09-05 2020-06-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
EP3137100B1 (fr) 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Récepteurs des lymphocytes t isolés et leurs procédés d'utilisation
EP3371811B1 (fr) * 2015-11-06 2022-11-23 Carver Scientific, Inc. Dispositif de mémoire électro-entropique
US11250328B2 (en) 2016-10-26 2022-02-15 Cognizant Technology Solutions U.S. Corporation Cooperative evolution of deep neural network structures
US11507844B2 (en) 2017-03-07 2022-11-22 Cognizant Technology Solutions U.S. Corporation Asynchronous evaluation strategy for evolution of deep neural networks
US11250314B2 (en) 2017-10-27 2022-02-15 Cognizant Technology Solutions U.S. Corporation Beyond shared hierarchies: deep multitask learning through soft layer ordering
EP3724819A4 (fr) 2017-12-13 2022-06-22 Cognizant Technology Solutions U.S. Corporation Architectures évolutives pour l'évolution de réseaux neuronaux profonds
WO2019118299A1 (fr) * 2017-12-13 2019-06-20 Sentient Technologies (Barbados) Limited Évolution de réseaux récurrents au moyen d'une programmation génétique
US11527308B2 (en) 2018-02-06 2022-12-13 Cognizant Technology Solutions U.S. Corporation Enhanced optimization with composite objectives and novelty-diversity selection
US11481639B2 (en) 2019-02-26 2022-10-25 Cognizant Technology Solutions U.S. Corporation Enhanced optimization with composite objectives and novelty pulsation
CA3129731A1 (fr) 2019-03-13 2020-09-17 Elliot Meyerson Systeme et procede permettant de mettre en ?uvre un reparametrage universel modulaire pour un apprentissage multitache profond a travers divers domaines
US11783195B2 (en) 2019-03-27 2023-10-10 Cognizant Technology Solutions U.S. Corporation Process and system including an optimization engine with evolutionary surrogate-assisted prescriptions
US11775841B2 (en) 2020-06-15 2023-10-03 Cognizant Technology Solutions U.S. Corporation Process and system including explainable prescriptions through surrogate-assisted evolution
WO2024011265A2 (fr) * 2022-07-08 2024-01-11 University Of Vermont And State Agricultural College Peptides antioxydants mitochondriaux

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643778A (en) 1994-02-17 1997-07-01 The Wistar Institute Of Anatomy & Biology RNA editing enzyme and methods of use thereof
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1998039446A2 (fr) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 proteines humaines secretees
EP0973898A2 (fr) 1997-04-10 2000-01-26 Genetics Institute, Inc. MARQUEURS SECRETES DE SEQUENCE EXPRIMEE (sEST)
WO1999006548A2 (fr) 1997-08-01 1999-02-11 Genset Est 5' pour proteines secretees sans specificite tissulaire
CA2311572A1 (fr) 1997-12-17 1999-06-24 Genset S.A. Adnc prolonges pour proteines secretees
US7122373B1 (en) 1998-05-14 2006-10-17 Nuvelo, Inc. Human genes and gene expression products V
EP1053319A2 (fr) 1998-01-28 2000-11-22 Chiron Corporation Genes humains et expression de produits genetiques ii
JP2003530816A (ja) 1998-09-28 2003-10-21 カイロン コーポレイション ヒト遺伝子および遺伝子発現産物
WO2000021991A1 (fr) 1998-10-15 2000-04-20 Genetics Institute, Inc. ETIQUETTES DE SEQUENCES EXPRIMEES SECRETEES (sESTs)
PT1200590E (pt) 1999-08-12 2009-03-24 Agensys Inc Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
AU7721500A (en) 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2001042302A1 (fr) 1999-12-06 2001-06-14 Japan Science And Technology Corporation PROTEINE ET ADNc HUMAINS
WO2001042451A2 (fr) 1999-12-08 2001-06-14 Genset ADNc HUMAINS PLEINE LONGUEUR CODANT POUR DES PROTEINES POTENTIELLEMENT SECRETEES
WO2001060860A2 (fr) 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes, compositions, kits, et procedes d'identification, d'evaluation, de prevention, et de traitement du cancer de la prostate
US20020068345A1 (en) 2000-05-24 2002-06-06 Challita-Eid Pia M. 98P7C3: homeodomain protein highly expressed in various cancers
US20040110668A1 (en) 2000-10-02 2004-06-10 Burgess Christopher C. Nucleic acid sequences differentially expressed in cancer tissue
CA2428716A1 (fr) 2000-11-14 2002-05-23 Regents Of The University Of Minnesota Methode d'identification de genes associes a la leucemie myeloide chronique
EP1409535A2 (fr) 2000-12-13 2004-04-21 Incyte Genomics, Inc. Proteines secretees humaines
CA2440747A1 (fr) 2001-03-15 2002-09-26 Hyseq, Inc. Nouveaux acides nucleiques et nouveaux polypeptides
AU2002307466A1 (en) 2001-04-20 2002-11-05 Millennium Pharmaceutical, Inc. Method for detecting breast cancer cells
EP1308459A3 (fr) 2001-11-05 2003-07-09 Research Association for Biotechnology Séquences d'ADN complementaires pleine longueur
US7449548B2 (en) * 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
EP2500438A3 (fr) * 2002-09-25 2012-11-28 Genentech, Inc. Compositions et procédés nouveaux pour le traitement du psoriasis

Also Published As

Publication number Publication date
AU2002362105A1 (en) 2003-06-23
US7615379B2 (en) 2009-11-10
WO2003050255A2 (fr) 2003-06-19
US20090275041A1 (en) 2009-11-05
US7659377B2 (en) 2010-02-09
US20090249502A1 (en) 2009-10-01
US20040102407A1 (en) 2004-05-27
US20100111991A1 (en) 2010-05-06
CA2469161A1 (fr) 2003-06-19
US20100297650A1 (en) 2010-11-25
IL200608A0 (en) 2011-07-31
JP2005516593A (ja) 2005-06-09
US8188228B2 (en) 2012-05-29
WO2003050255A3 (fr) 2005-01-06
IL162274A (en) 2010-04-15
IL200608A (en) 2011-11-30
EP1517606A4 (fr) 2007-11-14
IL206243A (en) 2012-09-24
AU2002362105B2 (en) 2007-11-29
US20120202208A1 (en) 2012-08-09
JP2010110325A (ja) 2010-05-20
US20030223990A1 (en) 2003-12-04
EP1517606A2 (fr) 2005-03-30
US7732584B2 (en) 2010-06-08
US7449548B2 (en) 2008-11-11
US7968099B2 (en) 2011-06-28

Similar Documents

Publication Publication Date Title
EP1427746A4 (fr) Systemes d'expression de proteines et d'acides nucleiques
EP1504099A4 (fr) Nouveaux acides nucleiques et polypeptides
EP1381621A4 (fr) Nouveaux acides nucleiques et polypeptides
EP1432800A4 (fr) Nouveaux acides nucleiques et polypeptides
EP1470238A4 (fr) Nouveaux acides nucleiques et polypeptides
EP1430112A4 (fr) Nouveaux acides nucleiques et polypeptides
IL162274A0 (en) A nucleic acid and protein designated 193p1e1b andcompositions containing the same
EP1368475A4 (fr) Nouveaux acides nucleiques et nouveaux polypeptides
AU2002365188A8 (en) Nucleic acid delivery and expression
EP1357186A4 (fr) Nouvelles proteines et adn correspondant
EP1186615A4 (fr) Proteine et adn de cette proteine
IL158293A (en) Nucleic acid and corresponding protein entitled 158p3d2 and pharmaceutical compositions containing the same
EP1293568A4 (fr) Nouvelle proteine et son adn
IL149679A0 (en) Nucleic acid construct and methods utilizing the same
GB0021008D0 (en) Protein and nucleic acid sequence
AU2001259240A1 (en) Novel stmst protein and nucleic acid mocecules and uses therefor
IL160651A0 (en) Nucleic acid and correspondidng protein entitled 205pib5 and pharmaceutical compositions containing the same
EP1428877A4 (fr) Nouvelle proteine et adn associe
EP1457557A4 (fr) Nouvelles proteines et adn correspondants
GB0117193D0 (en) Protein modification reagents
EP1373306A4 (fr) Proteines associees au cytoskeleton
EP1375656A4 (fr) Nouvelles proteines et adn codant pour elle
EP1409523A4 (fr) Acides nucleiques et polypeptides pancam
EP1285942A4 (fr) Derives de polypeptides et transporteurs d'acides nucleiques contenant ces derives
EP1370675A4 (fr) Nouveaux acides nucleiques et polypeptides